Compare Innodata Inc (INOD) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Innodata Inc vs Recursion Pharmaceuticals Inc — how do they compare? Innodata Inc trades at $62.17 (market cap $2.05B), while Recursion Pharmaceuticals Inc trades at $3.31 (market cap $1.81B). The key difference: Innodata Inc and Recursion Pharmaceuticals Inc are close in size by market cap, and Innodata Inc is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| INOD | RXRX | |
|---|---|---|
Market Cap | $2.05B | $1.81B |
Sector | Technology | Health |
52-Week High | $121.50 | $6.79 |
52-Week Low | $34.45 | $2.84 |
Enterprise Value | $1.80B | $1.33B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INOD trades at $61.40, down 1.33% today, but maintains a bullish technical signal with oscillators supporting upside momentum. The company reported strong Q2 2026 results, beating EPS estimates with $0.41 versus $0.21 expected, driven by 58% revenue growth and AI-driven demand expansion. Valuation ratios remain elevated with a P/E of 48.62, reflecting high growth expectations.
Outlook is positive given consistent earnings beats and AI sector tailwinds, but risks include premium valuation sensitivity and customer concentration. Analyst consensus is bullish with a $130 price target, suggesting significant upside potential if execution continues.
RXRX trades at $3.33, up 1.22% in the last session, with a bearish technical signal and RSI near overbought levels. The company reported a Q2 2026 earnings miss with revenue of $54M and a net loss of $519M, reflecting a net margin of -961.97%. Recent news highlights participation in investor conferences and a Genentech partnership advancement, but competitive pressures and slow revenue growth remain concerns.
Outlook is cautious due to persistent losses and high cash burn, though partnerships provide some validation. Risks include execution challenges in drug discovery and reliance on milestone payments. Analysts show a mixed stance with 40% buy ratings, but the stock faces headwinds from weak profitability and bearish technical trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Innodata Inc
Innodata is a global data engineering company that provides solutions for training AI models. It helps enterprises solve complex data challenges through high-quality data annotation and digital transformation.
Read more on INOD →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
